SCHEMBL30649028

SCHEMBL30649028

CC(C)(C)OC(=O)[C@@H](CCCCOS(C)(=O)=O)NC(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.51
KLK7 P49862 1/20 0.47
KLK5 Q9Y337 1/20 0.47
CTSL P07711 2/20 0.47
CTSS P25774 2/20 0.47
PSMB5 P28074 1/20 0.46
CTSK P43235 2/20 0.46
SIRT2 Q8IXJ6 2/20 0.46
SIRT1 Q96EB6 2/20 0.46
MAPT P10636 1/20 0.46
SIRT3 Q9NTG7 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9301974 0.97 SYK (0.52) SYKKLK7KLK5CTSLCTSS
SCHEMBL8592181 0.88 CTSK (0.49) SYKKLK7KLK5CTSSCTSK
SCHEMBL8592186 0.88 CTSK (0.49) SYKKLK7KLK5CTSSCTSK
SCHEMBL26641013 0.88 SIRT2 (0.55) CTSLCTSSCTSKSIRT2SIRT1
SCHEMBL26641008 0.88 SIRT2 (0.55) CTSLCTSSCTSKSIRT2SIRT1
SCHEMBL8671689 0.85 SIRT2 (0.53) CTSLCTSSCTSKSIRT2SIRT1
SCHEMBL26896562 0.85 CTSL (0.60) SYKCTSLCTSSCTSKSIRT2
SCHEMBL10166824 0.85 SYK (0.54) SYKKLK7KLK5CTSLCTSS
SCHEMBL6947000 0.85 SIRT2 (0.53) CTSLCTSSCTSKSIRT2SIRT1
SCHEMBL30649083 0.85 SYK (0.54) SYKKLK7KLK5CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230405157-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2023-12-21 US disclosed
WO-2023219952-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230405157-A1 MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF MC3R, MC1R, MC4R SYK 2416/4885KLK7 1503/4885KLK5 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.